IL1B and deep vein thrombosis: The landmark Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) inhibited interleukin 1β (IL-1B) in survivors of myocardial infarction and reduced cardiovascular events (171, 172).